toceranib phosphate profile

toceranib phosphate: a tyrosine kinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	16034840
CHEMBL ID	2103833
MeSH ID	M0538270

Synonym
toceranib phosphate (usan)
D08544
874819-74-6
pha-291639e
toceranib phosphate [usan]
24f9pf7j3r ,
toceranib phosphate
su-11654
unii-24f9pf7j3r
su 11654
su11654
CHEMBL2103833
toceranib (phosphate)
HY-10330A
CS-1231
S5272
toceranib phosphate [green book]
(z)-5-((5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide phosphate
1h-pyrrole-3-carboxamide, 5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(1-pyrrolidinyl)ethyl)-, phosphate (1:1)
5-[(z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]-2,4-dimethyl-n-[2-(pyrrolidin-1-yl)ethyl]-1h-pyrrole-3-carboxamide phosphate (1:1)
toceranib phosphate [mi]
AKOS027427177
toceranib phosphate(su 11654)
mfcd25372034
(z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide phosphate
su11654 phosphate
pha 291639 phosphate
CCG-269649
Q27253845
5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide;phosphoric acid
AS-57142
AKOS037645104
pha291639
BT162330
5-((z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-n-(2-(pyrrolidin-1-yl)ethyl)-1h-pyrrole-3-carboxamide phosphate (1:1)

Excerpt	Reference	Relevance
"Toceranib phosphate (TOC) is a multi-target receptor tyrosine kinase (RTK) inhibitor that exhibits activity against members of the split kinase family of RTKs."	( Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines. Breitbach, JT; Fenger, JM; Geisler, JA; Husbands, BD; Korec, DI; Louke, DS, 2021)	1.57
"Toceranib phosphate could prove to be a useful postoperative adjuvant treatment because of its modulation of the TME."	( Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H, 2020)	2.25

Excerpt	Reference	Relevance
"Toceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in an additional 50-60% of dogs. "	( Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma. Kisseberth, WC; London, CA; Russell, DS; Urie, BK, 2012)	1.82
"Toceranib phosphate has been licensed for the treatment of dogs with mast cell tumours."	( The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Frezoulis, P; Harper, A, 2022)	1.82
"Toceranib phosphate has been reported to provide clinical benefit (CB) in dogs with thyroid carcinoma, while its role in treatment-naïve thyroid tumours has not been well-described."	( Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018). Bello, NM; Biller, B; Hocker, S; Sheppard-Olivares, S; Szivek, A; Wood, E; Wouda, RM, 2020)	2.72
"Toceranib phosphate has been shown to be an efficacious therapy for canine mast cell tumors with increasing evidence that it may be beneficial in the medical management of neuroendocrine tumors."	( Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma. Boudreaux, B; Flesner, BK; Fletcher, JM; Smithee, T, )	1.11

Excerpt	Reference	Relevance
"Toceranib phosphate treatment might result in increased systolic blood pressures in dogs. "	( Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs. Markovic, LE; Stein, TJ; Stepien, RL; Tjostheim, SS, 2016)	2.27
"Treatment with toceranib phosphate (TOC) and firocoxib reduced the tumor size, which was defined as partial response (PR)."	( Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma. Ikeda, M; Kimura, J; Kishimoto, M; Kondo, H; Kushida, K; Ohmori, K; Okazawa, T; Osada, H, 2023)	2.69
"Treatment with toceranib phosphate was started."	( Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate. Boudreaux, BB; Dedeaux, AM; Langohr, IM, 2018)	1.06
"Treatment with toceranib phosphate, a tyrosine-kinase inhibitor, was initiated and well tolerated by the animal."	( TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR. Fitzgerald, SD; Harrison, T; Needle, D; Patterson, J; Thompson, KA, 2016)	0.77
"Treatment with toceranib phosphate resulted in complete response, despite the absence of exon-8 or exon-11 c-kit mutation."	( Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia). Baines, L; Elliott, JW; Parry, A; Swinbourne, F, 2017)	1.02

Excerpt	Reference	Relevance
" As concurrent use may be warranted for a given individual and the adverse event (AE) profile for each can be overlapping (gastrointestinal), a phase I trial was performed in tumour-bearing (non-mast cell) dogs to establish the safety of the combination using a standard 3+3 cohort design."	( Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Chon, E; Kubicek, LN; McCartan, L; Vail, DM, 2012)	0.66
" Preliminary data suggests that lower doses of toeceranib may be associated with a reduced adverse event profile while maintaining sufficient drug exposure to provide biologic activity."	( Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF, 2013)	0.63
" Response to therapy was assessed using standard RECIST criteria and adverse events were characterized using the VCOG-CTCAE."	( Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF, 2013)	0.63
"9 mg/kg every other day provide drug exposure considered sufficient for target inhibition while resulting in an adverse event profile substantially reduced from that associated with the label dose of toceranib."	( Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF, 2013)	0.63
" Toxicity was graded according to the Veterinary Comparative Oncology Group - common terminology criteria for adverse events(VCOG-CTCAE) and response was measured according to Response Evaluation In Solid Tumors (RECIST) criteria."	( Toxicity and response in cats with neoplasia treated with toceranib phosphate. Blackwood, L; Harper, A, 2017)	0.7
" Toxicities were graded using the Veterinary Cooperative Oncology Group - Common Terminology Criteria for Adverse Events criteria and compared to published data on TOC-associated GI toxicity."	( Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate. Boss, MK; LaRue, SM; Leary, D; Martin, T; Prebble, AR; Thamm, DH; Weishaar, KM, 2022)	0.93
" This study aimed to determine the tolerability and adverse event profile of combined toceranib and low dose meloxicam in cancer-bearing cats."	( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Keepman, SJ; Pellin, MA, 2022)	0.96
"02 mg/kg q24h was safe and well tolerated, with no cats being withdrawn due to adverse events from the drug combination."	( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Keepman, SJ; Pellin, MA, 2022)	0.96
"Low dose meloxicam combined with toceranib is safe and well tolerated in cancer-bearing cats."	( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Keepman, SJ; Pellin, MA, 2022)	0.96

Excerpt	Reference	Relevance
" The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs."	( Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Biller, BJ; Mitchell, L; Thamm, DH, )	0.13
"In addition to antitumor effects, these data support further investigations into the immunomodulatory effects of toceranib, administered alone or in combination with CYC in dogs with cancer."	( Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Biller, BJ; Mitchell, L; Thamm, DH, )	0.13
"To compare survival in dogs with recurrent or metastatic insulinomas that were treated with palliative therapy, alone or in combination with toceranib phosphate and to assess tolerability of the combined therapy in dogs."	( Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia. Alonso-Miguel, D; Clarés Moral, I; García-San José, P; González Sanz, S; Pérez-Alenza, MD, 2021)	1.06
"The use of toceranib combined with palliative treatment in dogs with suspect metastatic or recurrent insulinomas increased survival time and was adequate tolerated."	( Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia. Alonso-Miguel, D; Clarés Moral, I; García-San José, P; González Sanz, S; Pérez-Alenza, MD, 2021)	0.86
"Low dose meloxicam combined with toceranib is safe and well tolerated in cancer-bearing cats."	( Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Keepman, SJ; Pellin, MA, 2022)	0.96

Excerpt	Reference	Relevance
" Oral bioavailability was 76."	( Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Boucher, JF; Lesman, SP; Merritt, DA; Michels, GM; Yancey, MF, 2010)	0.65

Excerpt	Relevance	Reference
" Five dose-escalating cohorts, up to and including approved label dosage for toceranib and standard dosage for piroxicam, were completed without observing a frequency of dose-limiting AEs necessitating cohort closure."	( Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Chon, E; Kubicek, LN; McCartan, L; Vail, DM, 2012)	0.66
"7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74."	( Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Alvarez, F; Beaver, L; Bryan, J; Carreras, J; Clifford, C; Ettinger, S; Fulton, L; Gauthier, M; Gill, V; Gillings, S; Haney, S; Henry, C; Hershey, B; Higginbotham, ML; Hillman, L; Jones, P; Kiselow, M; Klein, MK; Krick, E; Ladue, T; London, C; Mathie, T; McNeill, C; Novasad, A; Phillips, B; Stingle, N; Thamm, D; Vail, DM; Vaughan, A; Vickery, K, 2012)	0.64
"Tyrosine kinase inhibitors (TKIs) and metronomic dosing of cyclophosphamide (CYC) can improve tumor control by suppression of regulatory T cells (Treg) and restoration of T cell-mediated immune responses in mice and humans."	( Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Biller, BJ; Mitchell, L; Thamm, DH, )	0.13
"While maintaining a standard toceranib dosage [2."	( Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study. Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM, 2016)	0.68
" Low-dose aspirin was started in addition to an increased dosage of enalapril (0."	( Toceranib phosphate-associated nephrotic syndrome in a dog: a case report. Donnelly, LL; Herrera, CL; Remerowski, SM, 2021)	2.06

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (6.38)	29.6817
2010's	58 (61.70)	24.3611
2020's	30 (31.91)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	17 (17.00%)	5.53%
Reviews	3 (3.00%)	6.00%
Case Studies	17 (17.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	63 (63.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.17	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
lomustine [no description available]	4.74	3	2	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.15	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.17	1	0	phthalimides; piperidones
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.21	1	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.15	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	2.61	2	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.91	2	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.17	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	11.67	90	14	pyrrole; secondary amine
thiazoles [no description available]	4.38	3	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.17	1	0	pyrrolizidine alkaloid
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.41	1	0
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.21	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
trimethoprim, sulfadoxine drug combination trimethoprim, sulfadoxine drug combination: combination of sulfadoxine & trimethoprim	2.21	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	3.85	2	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
firocoxib firocoxib: a COX-2 inhibitor; structure in first source. firocoxib : An enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs.	7.6	1	0	butenolide; cyclopropanes; enol ether; sulfone	antineoplastic agent; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
sorafenib [no description available]	2.17	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
carboplatin [no description available]	5.52	5	3
bromochloroacetic acid Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.	2.21	1	0	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.44	1	1	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
su 11652 SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.	2.01	1	0	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
oxalates Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.	2.21	1	0
masitinib [no description available]	4.38	3	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
piperidines Piperidines: A family of hexahydropyridines.	4.38	3	0
piroxicam [no description available]	9.96	4	2	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	3.8	1	1	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug

Condition	Relationship Strength	Studies	Trials
Bladder Cancer [description not available]	2.59	2	0
Canine Diseases [description not available]	10.68	68	12
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.59	2	0
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	2.59	2	0
Carcinoma, Anaplastic [description not available]	3.54	7	0
Cancer of Nose [description not available]	3.09	4	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	3.54	7	0
Benign Neoplasms [description not available]	8.86	21	6
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	8.86	21	6
Ache [description not available]	3.8	1	1
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	6.83	11	2
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	3.8	1	1
Bone Cancer [description not available]	5.71	6	1
Osteogenic Sarcoma [description not available]	6.4	7	2
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	5.71	6	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	6.4	7	2
Benign Mastocytoma [description not available]	4.2	3	1
A-V Dissociation [description not available]	2.41	1	0
Cardiac Failure [description not available]	2.41	1	0
Cardiac Cancer [description not available]	2.69	2	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.41	1	0
Hepatocellular Carcinoma [description not available]	7.6	1	0
Cancer of Liver [description not available]	2.6	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.6	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.6	1	0
Autoimmune Diabetes [description not available]	2.6	1	0
Rodent Diseases Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).	2.6	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.6	1	0
Sarcoma, Epithelioid [description not available]	4.04	2	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	9.04	2	1
Adenocarcinoma, Basal Cell [description not available]	3.6	7	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.6	7	0
Cancer of Pancreas [description not available]	3.62	7	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	3.62	7	0
Central Hypothyroidism [description not available]	2.61	2	0
Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.	2.61	2	0
Gastrointestinal Stromal Neoplasm [description not available]	2.88	3	0
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	7.88	3	0
Anal Gland Neoplasms Tumors or cancer of the anal gland.	2.8	3	0
Cancer of the Thyroid [description not available]	2.8	3	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.8	3	0
Adenocarcinoma Of Kidney [description not available]	2.58	2	0
Local Neoplasm Recurrence [description not available]	3.35	6	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.58	2	0
Joint Pain [description not available]	3.64	1	1
Osteoarthritis of Knee [description not available]	3.64	1	1
Innate Inflammatory Response [description not available]	3.64	1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.64	1	1
Arthralgia Pain in the joint.	3.64	1	1
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	3.64	1	1
Genetic Predisposition [description not available]	2.31	1	0
Lymph Node Metastasis [description not available]	2.31	1	0
Malignant Melanoma [description not available]	2.31	1	0
Congenital Epulides [description not available]	2.31	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.31	1	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	7.31	1	0
Adenoma, beta-Cell [description not available]	2.31	1	0
Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.	2.31	1	0
Breast Cancer [description not available]	2.55	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.55	2	0
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	2.31	1	0
Germinoblastoma [description not available]	2.15	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	7.15	1	0
Cancer of Skin [description not available]	5.78	7	3
Skin Neoplasms Tumors or cancer of the SKIN.	5.78	7	3
Cancer of Lung [description not available]	2.85	3	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.85	3	0
Cutaneous Mastocytosis [description not available]	4.71	3	2
Animal Mammary Carcinoma [description not available]	2.83	3	0
Congenital Familial Lymphedema [description not available]	2.17	1	0
Lymphangioendothelioma, Malignant [description not available]	2.52	2	0
Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes.	2.17	1	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.55	2	0
Hypertrophy, Right Ventricular Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.	2.17	1	0
Cardiac Remodeling, Ventricular [description not available]	2.17	1	0
Pulmonary Arterial Remodeling [description not available]	2.17	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.52	2	0
Pulmonary Hypertension [description not available]	2.17	1	0
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.17	1	0
Adrenal Cancer [description not available]	2.17	1	0
Pheochromocytoma, Extra-Adrenal [description not available]	2.17	1	0
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	7.17	1	0
Cancer of Gastrointestinal Tract [description not available]	2.17	1	0
Cholera Infantum [description not available]	3.9	2	1
Mast Cell Activation Disease [description not available]	4.2	3	1
Mastocytosis A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA).	4.2	3	1
Neoplasms, Sweat Gland [description not available]	2.21	1	0
Asthma, Bronchial [description not available]	2.21	1	0
Equine Diseases [description not available]	2.21	1	0
Emesis [description not available]	7.5	2	0
Encephalitis, West Nile Fever [description not available]	2.21	1	0
P carinii Infection [description not available]	2.21	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.21	1	0
Nephrosis Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.	2.21	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	2.5	2	0
West Nile Fever A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)	2.21	1	0
Pneumocystis Infections Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.	2.21	1	0
P carinii Pneumonia [description not available]	2.21	1	0
Mast-Cell Sarcoma A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.	4.95	8	1
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	2.21	1	0
Thoracic Neoplasms New abnormal growth of tissue in the THORAX.	2.21	1	0
Granulocytic Leukemia [description not available]	2.08	1	0
Chromosomal Translocation [description not available]	2.08	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.08	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	3.86	2	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	4.77	3	2
Angiosarcoma [description not available]	2.11	1	0
Cancer of Spleen [description not available]	2.11	1	0
Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)	2.11	1	0
Carcinoma, Epidermoid [description not available]	3.04	4	0
Cancer of Mouth [description not available]	2.55	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	3.04	4	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.55	2	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	3.53	1	1
Azotaemia [description not available]	2.15	1	0
Thrombopenia [description not available]	2.15	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.15	1	0
Blood Pressure, High [description not available]	2.13	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.13	1	0
Cancer of Kidney [description not available]	2.13	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.13	1	0
Dermatoses [description not available]	2.15	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.15	1	0
Disease Exacerbation [description not available]	2.05	1	0
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	2.05	1	0
Cancer of Paranasal Sinus [description not available]	2.07	1	0
Paranasal Sinus Neoplasms Tumors or cancer of the PARANASAL SINUSES.	2.07	1	0
Cancer of Head [description not available]	2.07	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.07	1	0
Granulocytic Leukemia, Chronic [description not available]	2.07	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.07	1	0
Recrudescence [description not available]	2.01	1	0
Metastase [description not available]	2.01	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.01	1	0

toceranib phosphate

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (94)

Market Indicators

Research Demand Index: 53.04

Study Types

toceranib phosphate

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (94)

Market Indicators

Research Demand Index: 53.04

Study Types

Related Drugs (27)

Related Conditions (134)